Caution needed for full correction in low astigmatism

Article

Caution should be used when considering full astigmatic correction for manifest cylinder of 0.5 D or less in myopic patients, according to the latest investigation in the Journal of Cataract and Refractive Surgery.

Caution should be used when considering full astigmatic correction for manifest cylinder of 0.5 D or less in myopic patients, according to the latest investigation in the Journal of Cataract and Refractive Surgery.

The retrospective cross-sectional data analysis, headed by Dr Andreas Frings, Department of Ophthalmology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, enrolled 448 eyes of 448 myopic patients with low astigmatism of 0.75 D or less.

The preoperative and postoperative outcome measures were manifest refraction spherical equivalent (MRSE), uncorrected distance visual acuity (UDVA) and corrected distance visual acuity. Astigmatic changes were recorded using the Alpins vector analysis.

Four months postoperatively the mean UDVA was 0.10 ± 0.13 logMAR and the mean MRSE was −0.05 ± 0.68 D. The preoperative groups demonstrated no significant differences in efficacy or safety.

The correction index, the magnitude of error, the index of success and the flattening index suggested astigmatic overcorrection for a preoperative cylinder of 0.25 D and 0.50 D.

To read the abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.